A Controlled Study of the Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Comparison With SA14-14-2 Vaccine in Infants and Toddlers in Thailand - Primary Vaccination and Long-term Follow-up to 5 Years Post-vaccination.

Trial Profile

A Controlled Study of the Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Comparison With SA14-14-2 Vaccine in Infants and Toddlers in Thailand - Primary Vaccination and Long-term Follow-up to 5 Years Post-vaccination.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 May 2014

At a glance

  • Drugs Japanese encephalitis vaccine (Primary)
  • Indications Japanese encephalitis
  • Focus Pharmacodynamics
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 08 Apr 2014 Primary endpoint 'Seroconversion-rate' has been met as published in Pediatric Infectious Disease Journal.
    • 08 Apr 2014 Results published in the Pediatric Infectious Disease Journal.
    • 11 Oct 2011 Actual end date Oct 2011 added as reported by ClincialTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top